P04578 (ENV_HV1H2) Human immunodeficiency virus type 1 group M subtype B (isolate HXB2)(HIV-1)
Envelope glycoprotein gp160 UniProtKBInterProInteractive Modelling
856 aa; Sequence (Fasta)
It is possible new templates exist for this target since these models were created.
Available Structures
124 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Ligands | ||
|---|---|---|---|---|---|---|
| Model of gp120, including variable regions, in complex with CD4 and 17b |
Heteromer P01730; | |||||
| Assess | ||||||
| Crystal structure of llama VHH antibody in complex with HIV-1 HXBC2 gp120 core |
Heteromer | 9×NAG; | ||||
| Assess | ||||||
| Crystal Structure of FH1 Fab bound to HXb2 HIV-1 gp120 core |
Heteromer | 1×NAG; 7×NAG; 2×NH4; 2×EDO; 1×SO4; | ||||
| Assess | ||||||
| HIV-1 HXBC2 GP120 ENVELOPE GLYCOPROTEIN COMPLEXED WITH CD4 AND INDUCED NEUTRALIZING ANTIBODY 17B |
Heteromer P01730; | 2×NAG; 12×NAG; 1×IPA; | ||||
| Assess | ||||||
| HIV-1 gp120 Envelope Glycoprotein Complexed with the Broadly Neutralizing CD4-Binding-Site Antibody… |
Heteromer P01834; | 13×NAG; | ||||
| Assess | ||||||
| Crystal structure of HIV-gp120 core in complex with CD4-binding site antibody b13, space group C222 |
Heteromer | 16×NAG; 2×EPE; 4×SO4; 1×GOL; | ||||
| Assess | ||||||
| Crystal structure of HIV-gp120 core in complex with CD4-binding site antibody b13, space group C2221 |
Heteromer | 28×NAG; 1×SO4; | ||||
| Assess | ||||||
| HIV-1 GP120 CORE COMPLEXED WITH CD4 AND A NEUTRALIZING HUMAN ANTIBODY |
Heteromer P01730; | 4×NAG; 7×NAG; | ||||
| Assess | ||||||
| Molecular structure for the HIV-1 gp120 trimer in the unliganded state |
Heteromer | |||||
| Assess | ||||||
| Molecular structure for the HIV-1 gp120 trimer in the b12-bound state |
Heteromer | |||||
| Assess | ||||||
| Molecular structure for the HIV-1 gp120 trimer in the CD4-bound state |
Heteromer | |||||
| Assess | ||||||
| Crystal structure of anti-HIV llama VHH antibody J3 in complex with HIV-1 C1086 gp120 |
Heteromer C6G099; | 7×NAG; 5×SO4; | ||||
| Assess | ||||||
| Crystal structure of anti-HIV llama VHH antibody A12 in complex with HIV-1 C1086 gp120 |
Heteromer C6G099; | 8×NAG; | ||||
| Assess | ||||||
| HIV-1 HXBC2 GP120 ENVELOPE GLYCOPROTEIN COMPLEXED WITH CD4 AND INDUCED NEUTRALIZING ANTIBODY 17B |
Heteromer P01730; | 2×NAG; 12×NAG; 1×IPA; | ||||
| Assess | ||||||
| Crystal structure of asymmetric HIV-1 gp41 containing all membrane anchors |
Heteromer | |||||
| Assess | ||||||
| Crystal Structure at 4.3 A Resolution of Glycosylated HIV-1 Clade A BG505 SOSIP.664 Prefusion Env T… |
Heteromer P01857; P0DOY2; Q2N0S6; | 6×NAG; 3×NAG; 3×NAG; 24×NAG; 3×NAG; 3×NAG; 3×NAG; 18×NAG; 3×SO4; | ||||
| Assess | ||||||
| Crystal structure of the germline-targeting HIV-1 gp120 engineered outer domain eOD-GT6 in complex … |
Heteromer | 2×NAG; | ||||
| Assess | ||||||
| Crystal structure of broad and potent HIV-1 neutralizing antibody PGT128 in complex with a glycosyl… |
Heteromer P01857; P0DOY2; Q75760; | 1×NAG; 1×NAG; | ||||
| Assess | ||||||
| Structure of T20/N39 |
Heteromer | |||||
| Assess | ||||||
| crystal structure of the HK20 Fab in complex with a gp41 mimetic 5- Helix |
Heteromer | |||||
| Assess | ||||||
| Structure of C34M/N36 |
Heteromer | |||||
| Assess | ||||||
| Structure of C34N126K/N36 |
Heteromer | |||||
| Assess | ||||||
| Structure of C34E136G/N36 |
Heteromer | |||||
| Assess | ||||||
| HIV GP41 CORE STRUCTURE |
Heteromer | |||||
| Assess | ||||||
| A new HIV fusion peptide inhibitor |
Heteromer | |||||
| Assess | ||||||
| Gp41-targeting HIV-1 fusion inhibitors with hook-like Ile-Asp-Leu tail |
Heteromer | 1×TAM; | ||||
| Assess | ||||||
| Crystal structure of C14linkmid/IQN17: a cross-linked inhibitor of HIV-1 entry bound to the gp41 hy… |
Heteromer P03069; | 3×CL; 3×N2P; | ||||
| Assess | ||||||
| Crystal structure of LP-46/N44 |
Heteromer | |||||
| Assess | ||||||
| Artificial HIV fusion inhibitor AP3 fused to the C-terminus of gp41 NHR |
Heteromer | 3×SO4; 3×EDO; 3×P4G; | ||||
| Assess | ||||||
| Crystal structure of HIV-1 fusion inhibitor MT-WQ-IDL bound to gp41 NHR |
Heteromer | |||||
| Assess | ||||||
| Crystal structure of HIV-1 fusion inhibitor SC29EK complexed with gp41 NHR (N44) |
Heteromer | |||||
| Assess | ||||||
| crystal structure of LN01 Fab in complex with an HIV-1 gp41 peptide |
Heteromer | 1×NAG; 2×PC; | ||||
| Assess | ||||||
| HIV-gp41 fusion inhibitor Sifuvirtide |
Heteromer | |||||
| Assess | ||||||
| Crystal structure of HIV-1 fusion inhibitor SC29EK complexed with gp41 NHR (N36) |
Heteromer | |||||
| Assess | ||||||
| Crystal structure of HP23L/N36 |
Heteromer | |||||
| Assess | ||||||
| Crystal structure of HP23LN36KR |
Heteromer | |||||
| Assess | ||||||
| Crystal structure of LP-11/N44 |
Heteromer | |||||
| Assess | ||||||
| Crystal Structure of a Generation 3 Influenza Hemagglutinin Stabilized Stem Complexed with the Broa… |
Heteromer D9IEJ2; Q6WG00; | 3×NAG; 3×NAG; | ||||
| Assess | ||||||
| Crystal structure of a generation 4 influenza hemagglutinin stabilized stem in complex with the bro… |
Heteromer Q6WG00; | |||||
| Assess | ||||||
| THE STRUCTURE OF AN HIV-1 SPECIFIC CELL ENTRY INHIBITOR IN COMPLEX WITH THE HIV-1 GP41 TRIMERIC CORE |
Heteromer P03069; P03377; | |||||
| Assess | ||||||
| Crystal structure of broad neutralizing antibody 10E8 with long epitope bound |
Heteromer | 7×PO4; | ||||
| Assess | ||||||
| Crystal structure of Fab460 in complex with MPER peptide |
Heteromer | |||||
| Assess | ||||||
| Crystal structure of the non-neutralizing HIV antibody 13H11 Fab fragment with a gp41 MPER-derived … |
Heteromer Q8TCD0; S6B291; | 1×EDO; | ||||
| Assess | ||||||
| crystal structure of LN01 Fab in complex with an HIV-1 gp41 peptide |
Heteromer | 1×NAG; 1×DPV; | ||||
| Assess | ||||||
| crystal structure of LN01 Fab in complex with an HIV-1 gp41 peptide |
Heteromer | 1×NAG; 2×PO4; 1×PC; | ||||
| Assess | ||||||
| PIE12 D-PEPTIDE AGAINST HIV ENTRY (IN COMPLEX WITH IQN17 Q577R RESISTANCE MUTANT) |
Heteromer P03069; | 6×CL; | ||||
| Assess | ||||||
| Crystal structure of the non-neutralizing HIV antibody 13H11 Fab fragment with a gp41 MPER-derived … |
Heteromer Q8TCD0; S6B291; | 1×NA; | ||||
| Assess | ||||||
| Crystal structure of Fab235 in complex with MPER peptide |
Heteromer | 1×GOL; | ||||
| Assess | ||||||
| Crystal structure of 10E8v4-5R+100cF Fab in complex with HIV-1 gp41 peptide |
Heteromer | |||||
| Assess | ||||||
| Crystal structure of the F240 antibody fragment bound to the HIV-1 gp41 immunodominant region |
Heteromer | 2×GOL; 1×ACT; | ||||
| Assess | ||||||
| Llama VHH 2E7 in complex with gp41 |
Heteromer | |||||
| Assess | ||||||
| Crystal structure of 4E10 modified with pyrene acetamide |
Heteromer | 6×GOL; 1×ACT; | ||||
| Assess | ||||||
| Crystal structure of broadly neutralizing anti-HIV-1 antibody 4E10, mutant Npro, with peptide bound |
Heteromer | 2×GOL; 1×PGE; 1×P6G; 1×CL; 1×ACT; | ||||
| Assess | ||||||
| Crystal Structure of non-neutralizing version of 4E10 (DeltaLoop) with epitope bound |
Heteromer | 4×GOL; 1×CL; | ||||
| Assess | ||||||
| Anti-HIV-1 broadly neutralizing antibody delta-loop 4E10 modified with pyrene acetamide |
Heteromer | 1×SO4; 1×NH4; 4×GOL; 1×CL; | ||||
| Assess | ||||||
| High-resolution crystal structure of ERAP1 in complex with 15mer phosphinic peptide |
Heteromer Q9NZ08; | 2×NAG; 1×ZN; 1×B3P; 21×EDO; 4×NA; 1×PPI; 2×NAG; | ||||
| Assess | ||||||
| Crystal Structure of non-neutralizing version of 4E10 (WDWD) with epitope bound |
Heteromer | 2×GOL; 2×CL; 1×ACT; | ||||
| Assess | ||||||
| Crystal structure of the Fab fragment of the human HIV-1 neutralizing antibody PGZL1.H4K3 in comple… |
Heteromer | 3×GOL; 3×PO4; | ||||
| Assess | ||||||
| Crystal structure of the germline PGZL1 (PGZL1_gVmDmJ) Fab in complex with MPER peptide epitope. |
Heteromer | 3×GOL; 1×SO4; | ||||
| Assess | ||||||
| Crystal structure of the Fab fragment of the human HIV-1 neutralizing antibody PGZL1 in complex wit… |
Heteromer | 1×44E; | ||||
| Assess | ||||||
| Crystal structure of the Fab fragment of the human HIV-1 neutralizing antibody PGZL1 in complex wit… |
Heteromer | 1×GOL; 1×SO4; | ||||
| Assess | ||||||
| Crystal structure of the 3D6 antibody fragment bound to the HIV-1 gp41 immunodominant region |
Heteromer | |||||
| Assess | ||||||
| Fab/epitope complex structure of rabbit monoclonal antibody R53 targeting an epitope in HIV-1 gp120… |
Heteromer | |||||
| Assess | ||||||
| Crystal structures in an anti-HIV antibody lineage from immunization of Rhesus macaques |
Heteromer | |||||
| Assess | ||||||
| STRUCTURE OF THE ANTIBODY 7B2 THAT CAPTURES HIV-1 VIRIONS |
Heteromer P01834; S6B291; | |||||
| Assess | ||||||
| Crystal Structure of HLA-B*57:01 with a modified HIV peptide RKV-Kyn |
Heteromer P01889; P61769; | 1×ACT; | ||||
| Assess | ||||||
| Crystal Structure of HLA-B*57:01 with an HIV peptide RKV |
Heteromer P01889; P61771; | |||||
| Assess | ||||||
| Crystal Structure of B4.2.3 T-Cell Receptor and H2-Dd P18-I10 Complex |
Heteromer P01887; P01900; | 4×EDO; | ||||
| Assess | ||||||
| Crystal structure of H-2Dd with C84-C139 disulfide in complex with gp120 derived peptide P18-I10 |
Heteromer P01900; P61769; | |||||
| Assess | ||||||
| Crystal structure of Fab.34.5.8 in complex with MHC-I (H2-Dd) |
Heteromer P01887; P01900; | 3×GOL; 1×EDO; | ||||
| Assess | ||||||
| Crystal structure of Fab.34.2.12 in complex with MHC-I (H2-Dd) |
Heteromer P01887; P01900; | 1×EDO; 1×GOL; | ||||
| Assess | ||||||
| Crystal structure of Fab.S19.8 in complex with MHC-I (H2-Dd) |
Heteromer P01887; P01900; | 1×SO4; 1×GOL; | ||||
| Assess | ||||||
| Crystal structure of the HIV-1 Cross Neutralizing Monoclonal Antibody 2F5 in complex with gp41 Pept… |
Heteromer Q8NF17; | |||||
| Assess | ||||||
| Crystal structure of HIV-1 broadly neutralizing antibody ACS202 |
Heteromer | 2×SO4; | ||||
| Assess | ||||||
| N123-VRC34_pI4 HIV neutralizing antibody in complex with HIV fusion peptide residue 512-519 |
Heteromer Q6GMX0; | |||||
| Assess | ||||||
| N123-VRC34_pI3 HIV neutralizing antibody in complex with HIV fusion peptide residue 512-519 |
Heteromer Q6GMX0; | |||||
| Assess | ||||||
| Structure of mouse vaccination-elicited HIV neutralizing antibody vFP5.01 in complex with HIV-1 fus… |
Heteromer | |||||
| Assess | ||||||
| Vaccine-elicited murine FP-targeting antibody vFP25.18 in complex with HIV fusion peptide (residue … |
Heteromer | |||||
| Assess | ||||||
| Vaccine-elicited NHP FP-targeting antibody DF2F-e.01 in complex with HIV fusion peptide (residue 51… |
Heteromer | |||||
| Assess | ||||||
| Vaccine-elicited NHP FP-targeting neutralizing antibody DF2F-b.04 in complex with HIV fusion peptid… |
Heteromer | |||||
| Assess | ||||||
| Vaccine-elicited NHP FP-targeting antibody 0PV-a.04 in complex with HIV fusion peptide (residue 512… |
Heteromer | 2×SO4; | ||||
| Assess | ||||||
| N123-VRC34.05 HIV neutralizing antibody in complex with HIV fusion peptide residue 512-519 |
Heteromer P0DOX5; Q6GMX0; | |||||
| Assess | ||||||
| Vaccine-elicited NHP FP-targeting antibody 13N024-a.01 in complex with HIV fusion peptide (residue … |
Heteromer | |||||
| Assess | ||||||
| Vaccine-elicited NHP FP-targeting neutralizing antibody 0PV-c.01 in complex with FP (residue 512-51… |
Heteromer | |||||
| Assess | ||||||
| Vaccine-elicited NHP FP-targeting antibody DF2F-a.01 in complex with HIV fusion peptide (residue 51… |
Heteromer | |||||
| Assess | ||||||
| Vaccine-elicited murine FP-targeting antibody vFP6.01 in complex with HIV fusion peptide (residue 5… |
Heteromer | |||||
| Assess | ||||||
| Structure of vaccine-elicited diverse HIV-1 neutralizing antibody vFP1.01 in complex with HIV-1 fus… |
Heteromer | 2×SO4; | ||||
| Assess | ||||||
| Vaccine-elicited NHP FP-targeting neutralizing antibody 0PV-b.01 in complex with HIV fusion peptide… |
Heteromer | |||||
| Assess | ||||||
| Vaccine-elicited NHP FP-targeting neutralizing antibody 0PV-a.01 in complex with FP (residue 512-51… |
Heteromer | 2×SO4; 1×CA; | ||||
| Assess | ||||||
| Vaccine-elicited NHP FP-targeting HIV neutralizing antibody DFPH-a.15 in complex with HIV fusion pe… |
Heteromer | |||||
| Assess | ||||||
| Vaccine-elicited NHP FP-targeting neutralizing antibody A12V163-a.02 in complex with HIV fusion pep… |
Heteromer | |||||
| Assess | ||||||
| Vaccine-elicited mouse FP-targeting neutralizing antibody vFP16.02 with S48K mutation in light chai… |
Heteromer | |||||
| Assess | ||||||
| Vaccine-elicited NHP FP-targeting HIV neutralizing antibody A12V163-a.01 in complex with HIV fusion… |
Heteromer | |||||
| Assess | ||||||
| Vaccine-elicited NHP FP-targeting neutralizing antibody DF1W-a.01 in complex with HIV fusion peptid… |
Heteromer | |||||
| Assess | ||||||
| Crystal structure of the HIV-1 Cross Neutralizing Antibody 2F5 in complex with gp41 Peptide ELLELDK… |
Heteromer Q6PYX1; | |||||
| Assess | ||||||
| Model of the HIV-1 gp41 membrane-proximal external region, transmembrane domain and cytoplasmic tail | homo-3-mer | |||||
| Assess | ||||||
| Structure of the HIV-1 gp41 transmembrane domain and cytoplasmic tail | homo-3-mer | |||||
| Assess | ||||||
| Model of the HIV-1 gp41 membrane-proximal external region, transmembrane domain and cytoplasmic tai… | homo-3-mer | |||||
| Assess | ||||||
| HIV-1 gp41 variant V549E resistance mutation | homo-3-mer | |||||
| Assess | ||||||
| HIV-1 gp41 variant Q552R and L555M resistance mutations | homo-3-mer | |||||
| Assess | ||||||
| Structure of the HIV-1 gp41 transmembrane domain and cytoplasmic tail (LLP2) | homo-3-mer | |||||
| Assess | ||||||
| INTERACTIONS BETWEEN HIV-1 GP41 CORE AND DETERGENTS AND THEIR IMPLICATIONS FOR MEMBRANE FUSION | homo-3-mer | |||||
| Assess | ||||||
| Crystal structure analysis of the gp41 core mutant | homo-3-mer | |||||
| Assess | ||||||
| Gp41-targeting HIV-1 fusion inhibitors with helical Ile-Asp-Leu tail | homo-3-mer | |||||
| Assess | ||||||
| Crystal structure analysis of gp41 core mutant | homo-3-mer | |||||
| Assess | ||||||
| HELICAL INTERACTIONS IN THE HIV-1 GP41 CORE REVEALS STRUCTURAL BASIS FOR THE INHIBITORY ACTIVITY OF… | homo-3-mer | |||||
| Assess | ||||||
| INTERACTIONS BETWEEN HIV-1 GP41 CORE AND DETERGENTS AND THEIR IMPLICATIONS FOR MEMBRANE FUSION | homo-3-mer | |||||
| Assess | ||||||
| HIV-1 gp41 coiled-coil pocket IQN22 | homo-3-mer | |||||
| Assess | ||||||
| HIV-1 gp41 coiled-coil pocket IQN17 | homo-3-mer | 3×ACY; 1×CL; | ||||
| Assess | ||||||
| Oligomeric Structure of the HIV gp41 MPER-TMD in Phospholipid Bilayers | homo-3-mer | |||||
| Assess | ||||||
| Artificial HIV fusion inhibitor AP1 fused to the C-terminus of gp41 NHR | homo-3-mer | 5×GOL; | ||||
| Assess | ||||||
| Artificial HIV fusion inhibitor AP2 fused to the C-terminus of gp41 NHR | homo-3-mer | 3×MG; 6×PEG; | ||||
| Assess | ||||||
| NMR assignment and structure of a peptide derived from the fusion peptide of HIV-1 gp41 in the pres… | monomer | |||||
| Assess | ||||||
| NMR assignment and structure of a peptide derived from the fusion peptide of HIV-1 gp41 in the pres… | monomer | |||||
| Assess | ||||||
| Crystal structure of the germline-targeting HIV-1 gp120 engineered outer domain, eOD-GT6 | monomer | 2×NAG; | ||||
| Assess | ||||||
| HIV-1 gp41 clade B double alanine mutant Membrane Proximal External Region peptide in DPC micelle | monomer | |||||
| Assess | ||||||
| NMR assignment and structure of a peptide derived from the membrane proximal external region of HIV… | monomer | |||||
| Assess | ||||||
| NMR assignment and structure of a peptide derived from the membrane proximal external region of HIV… | monomer | |||||
| Assess | ||||||
| HIV-1 gp41 Membrane Proximal Ectodomain Region peptide in DPC micelle | monomer | |||||
| Assess | ||||||
| NMR assignment and structure of a peptide derived from the trans-membrane region of HIV-1 gp41 in t… | monomer | |||||
| Assess | ||||||
| NMR assignment and structure of a peptide derived from the membrane proximal external region of HIV… | monomer | |||||
| Assess | ||||||
| NMR assignment and structure of a peptide derived from the fusion peptide of HIV-1 gp41 in the pres… | monomer | |||||
| Assess | ||||||
| Solution ensemble structures of HIV-1 gp41 2F5 mAb epitope | monomer | |||||
| Assess | ||||||
| Solution NMR Structure of Unbound P18-I10 | monomer | |||||
| Assess | ||||||
5 SWISS-MODEL models
| Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 8eu8.1.A | homo-3-mer | 0.66 | 3×NAG; | 75.32 | ||
| Assess | ||||||
| 8eu8.1.A | homo-3-mer | 0.66 | 3×NAG; | 75.32 | ||
| Assess | ||||||
| 8eu8.1.A | homo-3-mer | 0.66 | 3×NAG; | 75.32 | ||
| Assess | ||||||
| 7n6u.1.A | homo-3-mer | 0.56 | 1×NAG; 3×83G; | 89.85 | ||
| Assess | ||||||
| 7n6u.1.A | homo-3-mer | 0.56 | 1×NAG; 3×83G; | 89.85 | ||
| Assess | ||||||